肾康注射液联合血液透析治疗慢性肾功能衰竭的临床效果分析

Clinical effects of chronic renal failure by Shenkang injection combine with hematodialysis

目的:探讨肾康注射液联合血液透析治疗慢性肾功能衰竭的临床效果。方法:按照随机数字表法将92例慢性肾功能衰竭患者均分为实验组和对照组,分别给予肾康注射液联合血液透析治疗和单纯血液透析治疗,比较两组治疗效果。结果:2组患者治疗后Scr和BUN水平均明显下降,与同组治疗前比较,有显著差异;治疗后2组间Scr和BUN水平比较,差异无统计学意义;2组患者治疗后UA水平均明显下降,与同组治疗前比较,有显著差异;实验组患者治疗后UA水平明显低于对照组,有显著差异;2组患者治疗前后HGB水平均未发生明显变化,组间比较差异无统计学意义;2组患者治疗后中医症候积分均明显下降,与同组治疗前比较,有显著差异;治疗后实验组患者中医症候积分明显低于对照组,有显著差异;实验组患者中医症候总有效率明显高于对照组,有显著差异;实验组患者治疗后RBC、HGB、TP、ALB水平均明显提高,与治疗前比较,有显著差异;实验组患者治疗后RBC、HGB、TP、ALB水平均明显高于对照组,有显著差异;2组患者治疗后生存质量评分均明显升高,与同组治疗前比较,有显著差异;实验组患者治疗后生存质量评分明显高于对照组,有显著差异。结论:在血液透析基础上加用肾康注射液能够有效减少透析次数,改善患者肾功能和临床症状,改善患者营养状态,提高生存质量,临床优势明显。

Objective： To explore the clinical effects of chronic renal failure by Shenkang injection combine with hematodialysis. Methods： 92 cases of patients with chronic renal failure were randomly divided into experiment group and control group. The control group were treated by hematodialysis,the experiment group were treated by Shenkang injection combine with hematodialysis. The clinical effects were compared for the two groups. Results ： The levels of Scr,BUN after treatment for the two groups were lower than before treatment（ P〈0. 05）; There has no significant difference on the levels of Scr,BUN（ P 〉0. 05）; The levels of UA after treatment for the two groups were lower than before（ P〈0. 05）; The levels of UA after treatment for the experiment group were lower than the control group（ P〈0. 05）; There has no significant difference on the levels of HGB（ P〉 0. 05）; The TCM symptoms score after treatment for the two groups were lower than before treatment（ P〈0. 05）; The TCM symptoms score after treatment for the experiment group were lower than the control group（ P〈0. 05）; The total effective rate of TCM symptoms for the experiment group were higher than the control group（ P〈0. 05）; The levels of RBC,HGB,TP,ALB after treatment for the experiment group were higher than before treatment and the control group（ P〈0. 05）; The scores of physical health,general health for the experiment group were higher than the control group（ P〈0. 05）; The quality of life after treatment for the two groups were higher than before（ P〈0. 05）; The quality of life after treatment for the experiment group were lower than the control group（ P〈0. 05）. Conclusion： It can reduce the number of dialysis for the patients with chronic renal failure by Shenkang injection combine with hematodialysis. It can improve the renal function,clinical symptoms,nutritional status,increase the quality of life,it has clinical advantages.